BACKGROUND AND PURPOSE: beta(1)- and beta(2)-adrenoceptors coexist in rat heart but beta(2)-adrenoceptor-mediated inotropic effects are hardly detectable, possibly due to phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide (300 nmol x L(-1)) and the PDE4 inhibitor rolipram (1 micromol x L(-1)) on the effects of (-)-catecholamines. EXPERIMENTAL APPROACH: Cardiostimulation evoked by (-)-noradrenaline (ICI118551 present) and (-)-adrenaline (CGP20712A present) through beta(1)- and beta(2)-adrenoceptors, respectively, was compared on sinoatrial beating rate, left atrial and ventricular contractile force in isolated tissues from Wistar rats. L-type Ca(2+)-current (I(Ca-L)) was assessed with whole-cell patch clamp. KEY RESULTS: Rolipram caused sinoatrial tachycardia. Cilostamide and rolipram did not enhance chronotropic potencies of (-)-noradrenaline and (-)-adrenaline. Rolipram but not cilostamide potentiated atrial and ventricular inotropic effects of (-)-noradrenaline. Cilostamide potentiated the ventricular effects of (-)-adrenaline but not of (-)-noradrenaline. Concurrent cilostamide + rolipram uncovered left atrial effects of (-)-adrenaline. Both rolipram and cilostamide augmented the (-)-noradrenaline (1 micromol x L(-1)) evoked increase in I(Ca-L). (-)-Adrenaline (10 micromol x L(-1)) increased I(Ca-L) only in the presence of cilostamide but not rolipram. CONCLUSIONS AND IMPLICATIONS: PDE4 blunts the beta(1)-adrenoceptor-mediated inotropic effects. PDE4 reduces basal sinoatrial rate in a compartment distinct from compartments controlled by beta(1)- and beta(2)-adrenoceptors. PDE3 and PDE4 jointly prevent left atrial beta(2)-adrenoceptor-mediated inotropy. Both PDE3 and PDE4 reduce I(Ca-L) responses through beta(1)-adrenoceptors but the PDE3 component is unrelated to inotropy. PDE3 blunts both ventricular inotropic and I(Ca-L) responses through beta(2)-adrenoceptors.
BACKGROUND AND PURPOSE: beta(1)- and beta(2)-adrenoceptors coexist in rat heart but beta(2)-adrenoceptor-mediated inotropic effects are hardly detectable, possibly due to phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide (300 nmol x L(-1)) and the PDE4 inhibitor rolipram (1 micromol x L(-1)) on the effects of (-)-catecholamines. EXPERIMENTAL APPROACH: Cardiostimulation evoked by (-)-noradrenaline (ICI118551 present) and (-)-adrenaline (CGP20712A present) through beta(1)- and beta(2)-adrenoceptors, respectively, was compared on sinoatrial beating rate, left atrial and ventricular contractile force in isolated tissues from Wistar rats. L-type Ca(2+)-current (I(Ca-L)) was assessed with whole-cell patch clamp. KEY RESULTS:Rolipram caused sinoatrial tachycardia. Cilostamide and rolipram did not enhance chronotropic potencies of (-)-noradrenaline and (-)-adrenaline. Rolipram but not cilostamide potentiated atrial and ventricular inotropic effects of (-)-noradrenaline. Cilostamide potentiated the ventricular effects of (-)-adrenaline but not of (-)-noradrenaline. Concurrent cilostamide + rolipram uncovered left atrial effects of (-)-adrenaline. Both rolipram and cilostamide augmented the (-)-noradrenaline (1 micromol x L(-1)) evoked increase in I(Ca-L). (-)-Adrenaline (10 micromol x L(-1)) increased I(Ca-L) only in the presence of cilostamide but not rolipram. CONCLUSIONS AND IMPLICATIONS: PDE4 blunts the beta(1)-adrenoceptor-mediated inotropic effects. PDE4 reduces basal sinoatrial rate in a compartment distinct from compartments controlled by beta(1)- and beta(2)-adrenoceptors. PDE3 and PDE4 jointly prevent left atrial beta(2)-adrenoceptor-mediated inotropy. Both PDE3 and PDE4 reduce I(Ca-L) responses through beta(1)-adrenoceptors but the PDE3 component is unrelated to inotropy. PDE3 blunts both ventricular inotropic and I(Ca-L) responses through beta(2)-adrenoceptors.
Authors: H Gong; D L Adamson; H K Ranu; W J Koch; J F Heubach; U Ravens; O Zolk; S E Harding Journal: Br J Pharmacol Date: 2000-10 Impact factor: 8.739
Authors: Simon J MacKenzie; George S Baillie; Ian McPhee; Carolynn MacKenzie; Rachael Seamons; Theresa McSorley; Jenni Millen; Matthew B Beard; Gino van Heeke; Miles D Houslay Journal: Br J Pharmacol Date: 2002-06 Impact factor: 8.739
Authors: Faraz Afzal; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Finn Olav Levy; Tor Skomedal; Jan-Bjørn Osnes; Eirik Qvigstad Journal: Br J Pharmacol Date: 2011-01 Impact factor: 8.739
Authors: Peter Molenaar; Torsten Christ; Rizwan I Hussain; Andreas Engel; Emanuel Berk; Katherine T Gillette; Lu Chen; Alejandro Galindo-Tovar; Kurt A Krobert; Ursula Ravens; Finn Olav Levy; Alberto J Kaumann Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: Caroline Bull Melsom; Rizwan Iqbal Hussain; Øivind Ørstavik; Jan Magnus Aronsen; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-09-13 Impact factor: 3.000
Authors: Delphine Mika; Pierre Bobin; Martine Pomérance; Patrick Lechêne; Ruth E Westenbroek; William A Catterall; Grégoire Vandecasteele; Jérôme Leroy; Rodolphe Fischmeister Journal: Cardiovasc Res Date: 2013-08-09 Impact factor: 10.787